Literature DB >> 29420767

Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid.

Richard Kwizera1, Andrew Akampurira1, Tadeo K Kandole1, Maria S Nabaggala1, Darlisha A Williams1,2, Andrew Kambugu1,2, David B Meya1,3,2, Joshua Rhein1,2, David R Boulware2.   

Abstract

Cerebrospinal fluid (CSF) culture can determine a quantitative viability of Cryptococcus yeasts; however, culture has a long turnaround-time. The TC20 automated cell counter (Bio-Rad) is a benchtop instrument used to count cells in 30 seconds. In vitro studies suggest trypan blue staining can distinguish between viable and dead cryptococcal yeasts. We hypothesized that trypan blue staining with automated cell counting may provide rapid quantification of viable CSF Cryptococcus yeasts. In sum, 96 HIV-infected participants with cryptococcal meningitis were enrolled and provided 194 CSF specimens in Kampala, Uganda. Cryptococcosis was diagnosed by CSF cryptococcal antigen (CRAG). CSF was stained with trypan blue and quantified yeasts with the TC20 cell counter. We compared the log10 transformed cell counter readings with gating of 4-10 μm versus log10 quantitative Cryptococcus cultures/ml. TC20 showed more positive results (95.4%) overall than culture (78.4%) with reference to CSF CRAG. TC20 had higher readings compared to culture in most cases with only a 25% level of agreement between the two methods. TC20 had a poor correlation to culture throughout the 14 days of antifungal therapy. The median of log10 transformed counts were 5.22 (IQR = 4.79-5.44) for the TC20 and 3.99 (IQR = 2.59-5.14) for culture. Overall, a linear regression showed no significant relationship between the TC20 and culture (r = -0.0025; P = .92). TC20 automated cell counting with trypan blue staining was poorly predictive of the quantitative CSF culture and could not be used as a substitute for quantitative culture.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29420767      PMCID: PMC6251685          DOI: 10.1093/mmy/myx076

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

1.  Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings.

Authors:  A K Musubire; B D Meya; H Mayanja-Kizza; R Lukande; L D Wiesner; P Bohjanen; R D R Boulware
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

2.  Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults.

Authors:  Neil French; Katherine Gray; Christine Watera; Jessica Nakiyingi; Eric Lugada; Michael Moore; David Lalloo; James A G Whitworth; Charles F Gilks
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

Review 3.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

4.  Medium containing trypan blue and antibiotics for the detection of Cryptococcus neoformans in clinical samples.

Authors:  R M Vickers; J J McElligott; J D Rihs; B Postic
Journal:  Appl Microbiol       Date:  1974-01

Review 5.  Cryptococcal disease and the burden of other fungal diseases in Uganda; Where are the knowledge gaps and how can we fill them?

Authors:  R Parkes-Ratanshi; B Achan; R Kwizera; A Kambugu; D Meya; D W Denning
Journal:  Mycoses       Date:  2015-10       Impact factor: 4.377

6.  Rapid microscopy and use of vital dyes: potential to determine viability of Cryptococcus neoformans in the clinical laboratory.

Authors:  Brendan J McMullan; Desmarini Desmarini; Julianne T Djordjevic; Sharon C-A Chen; Michael Roper; Tania C Sorrell
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

7.  Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis.

Authors:  Jonathan Dyal; Andrew Akampurira; Joshua Rhein; Bozena M Morawski; Reuben Kiggundu; Henry W Nabeta; Abdu K Musubire; Nathan C Bahr; Darlisha A Williams; Tihana Bicanic; Robert A Larsen; David B Meya; David R Boulware
Journal:  Med Mycol       Date:  2016-01-14       Impact factor: 4.076

8.  Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast.

Authors:  David R Boulware; Melissa A Rolfes; Radha Rajasingham; Maximilian von Hohenberg; Zhenpeng Qin; Kabanda Taseera; Charlotte Schutz; Richard Kwizera; Elissa K Butler; Graeme Meintjes; Conrad Muzoora; John C Bischof; David B Meya
Journal:  Emerg Infect Dis       Date:  2014-01       Impact factor: 6.883

9.  Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis.

Authors:  Emma J Robertson; Grace Najjuka; Melissa A Rolfes; Andrew Akampurira; Neena Jain; Janani Anantharanjit; Maximilian von Hohenberg; Manlio Tassieri; Allan Carlsson; David B Meya; Thomas S Harrison; Bettina C Fries; David R Boulware; Tihana Bicanic
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

10.  Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Authors:  Joshua Rhein; Bozena M Morawski; Kathy Huppler Hullsiek; Henry W Nabeta; Reuben Kiggundu; Lillian Tugume; Abdu Musubire; Andrew Akampurira; Kyle D Smith; Ali Alhadab; Darlisha A Williams; Mahsa Abassi; Nathan C Bahr; Sruti S Velamakanni; James Fisher; Kirsten Nielsen; David B Meya; David R Boulware
Journal:  Lancet Infect Dis       Date:  2016-03-10       Impact factor: 25.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.